Kelly Yoo | Precision Medicine | Best Scholar Award

Published on by Top Pharmaceutical

Dr. Kelly Yoo | Precision Medicine | Best Scholar Award

Kelly Yoo at Stanford University | United States

Dr. Kelly H. Yoo is a physician-scientist specializing in neurosurgery and neuro-oncology, currently conducting postdoctoral research at Stanford University. Her work bridges translational neuroscience, radiosurgery, and artificial intelligence in clinical applications. She has authored numerous peer-reviewed articles and case studies on stereotactic radiosurgery, spinal disorders, and brain metastases. Dr. Yoo has received multiple international awards and fellowships for her academic excellence and research leadership. As a committed member of professional organizations and advisory boards, she contributes to global health, clinical innovation, and medical education. Her research efforts aim to improve patient outcomes through technology-enhanced, precision-targeted therapies.

Publication Profile 

Scopus

Education 

Dr. Kelly Yoo earned her International Baccalaureate Diploma and graduated. She later obtained her MD with top distinction and completed her Doctorate (Dr. med., magna cum laude) from Heidelberg University School of Medicine. Her academic path included rigorous clinical, research, and methodological training. She completed multiple advanced certifications, including GCP, IRB, and Clinical Trial Investigator courses. She studied Fundamental Neuroscience for Neuroimaging at Johns Hopkins University and holds licenses and fellowships from institutions in Germany and the U.S., further enhancing her global medical and scientific competency.

Experience 

Dr. Yoo currently serves as a postdoctoral fellow at Stanford University, focusing on clinical and translational research in neurosurgery. She completed a clinician-scientist residency track in Baden-Württemberg and has worked across Europe and North America in academic medical centers. She is active in multiple professional societies, including AANS, CNS, and EANO. Dr. Yoo has held leadership roles in Stanford’s postdoc community and initiated several mentorship and international programs. Her academic career includes significant contributions to radiosurgical research and spinal navigation, leveraging both clinical experience and data-driven methodologies to explore innovative therapeutic solutions.

Awards and Honors 

Dr. Kelly Yoo has received numerous prestigious accolades, including the SPARK at Stanford Grant Award, Wu Tsai Neurosciences Interdisciplinary Fellowship, and multiple scholarships from the German Academic International Network (GAIN). She was also awarded the E-Fellows Gifted Education Scholarship and earned top academic distinctions from Heidelberg University and the International Baccalaureate program. She has consistently ranked in the top percentile across educational stages and received first-place honors in international mathematics competitions. Her recognitions reflect a long-standing commitment to academic excellence, scientific innovation, and leadership in neuroscience, medicine, and global health initiatives.

Research Focus 

Dr. Yoo’s research primarily centers on stereotactic radiosurgery, neuro-oncology, spinal disorders, and the integration of AI and neuroimaging into surgical planning and treatment. She investigates the clinical applications of advanced radiological techniques in treating recurrent and metastatic brain and spinal tumors. Her recent work explores synergistic effects between radiosurgery and immunotherapy and the cost-effectiveness of neurosurgical interventions. She also contributes to studies on spinal navigation, robotic-assisted surgery, and PET/MRI-guided interventions. Her interdisciplinary focus aims to enhance precision medicine and outcome prediction models in neurosurgery by blending clinical insight with computational innovation.

Publication Top Notes

Suspected and surgically managed cauda equina syndrome nationwide: epidemiological trends and socioeconomic factors influencing access to care

Trends in Sacroiliac Joint Fusion Costs and Utilization in the Privately Insured Population

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Dr. Nigatu Gebrehiwot, Zhengzhou University, China

Dr. Nigatu Gebrehiwot is a dedicated PhD candidate in Pharmacology at Zhengzhou University, China, specializing in drug safety evaluation. He holds a Master’s in Clinical and Administrative Pharmacy from Xi’an Jiaotong University and a Bachelor of Pharmacy from Mekelle University, where he was recognized as an outstanding student. A published researcher and global presenter, Dr. Gebrehiwot has earned accolades including recognition at ISPOR in Barcelona. He is actively involved in multiple international scientific societies and brings strong expertise in pharmacotherapy, academic writing, and collaborative healthcare research. His work explores methionine metabolism and innovative therapeutic strategies.

Publication Profile

Orcid

Education

Dr. Nigatu Gebrehiwot holds a Master’s degree in Clinical and Administrative Pharmacy from Xi’an Jiaotong University, where his research earned an award at the 21st European Congress ISPOR Health Outcome Research Conference in Barcelona, Spain. 🏅 He also earned a Bachelor’s degree in Pharmacy from Mekelle University, where he was recognized as the most outstanding student in his class. 🎓 His academic achievements reflect his dedication to advancing the field of pharmacy, blending clinical expertise with research excellence. Dr. Gebrehiwot’s work continues to impact the healthcare landscape positively.

Experience

Dr. Nigatu Gebrehiwot is currently a Ph.D. candidate in Pharmacology at the Center for Drug Safety Evaluation and Research, Zhengzhou University, Henan, China, since September 2022. 🎓 Prior to this, he served as the Principal Scientific Officer at the Federal Ministry of Health (FMOH) in Ethiopia from June 2020 to 2021. During his tenure, Dr. Gebrehiwot managed national disease programs and medicines, overseeing the funding and evaluation of treatment guidelines and drug therapy protocols in accordance with Ethiopian legislation and EFDA guidelines. 💊 He also led technical committees focused on antimicrobial therapy, cancer, and chronic disease management.

Awards

Dr. Nigatu Gebrehiwot received a prestigious award for his research abstract at the 21st European Congress ISPOR Health Outcome Research conference in Barcelona, Spain. 🏆 This recognition underscores the significant impact of his work in the field of pharmacology and health outcome research. 🌍 His contributions continue to advance knowledge and influence healthcare practices, making him a respected figure in his field. 💡 Dr. Gebrehiwot’s dedication to research excellence and his ability to address critical health issues have earned him well-deserved acknowledgment on an international stage.

Research Focus

Dr. Nigatu Tadesse’s research primarily focuses on molecular alterations in disease processes, with an emphasis on metabolic pathways and their potential as diagnostic and therapeutic targets. His work on gastric intestinal metaplasia and methionine metabolism sheds light on novel approaches to diagnosis and treatment. Additionally, Dr. Tadesse has contributed significantly to pharmacology, particularly the study of traditional medicines like Dioscorea zingiberensis, investigating its phytochemistry, clinical applications, and toxicity. His research also extends to industrial processes, such as wastewater treatment in diosgenin production. His interdisciplinary work connects biomedicine, pharmacology, and environmental science.

Publication Top Notes

Molecular Alterations in Gastric Intestinal Metaplasia Shed Light on Alteration of Methionine Metabolism: Insight into New Diagnostic and Treatment Approaches

Knowledge, attitude and antibiotic prescribing patterns of medical doctors providing free healthcare in the outpatient departments of public hospitals in Sierra Leone: A national cross-sectional study

Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity

First total synthesis of a novel amide alkaloid derived from Aconitum taipeicum and its anticancer activity

Methods to treat the industrial wastewater in diosgenin enterprises produced from Diosorea zingiberensis C. H. Wright

Safety investigation on total steroid saponins extracts from Dioscorea zingiberensis C.H. Wright: Sub-acute and chronic toxicity studies on dogs

Chen Xie | Gene Therapy | Best Researcher Award

Published on by Top Pharmaceutical

Chen Xie | Gene Therapy | Best Researcher Award

Assoc. Prof. Dr. Chen Xie, Medical Research Center, the Eighth Affiliated Hospital of Sun Yat-sen University, China

Assoc. Prof. Dr. Chen Xie is a distinguished researcher at the Medical Research Center, Eighth Affiliated Hospital of Sun Yat-Sen University. With a Ph.D. in Biochemical Engineering from Huaqiao University and postdoctoral experience in genetics at Sun Yat-Sen University, his work focuses on inflammation, DNA damage, senescence, and noncoding RNAs. 🧬 He has published eight impactful papers in journals such as Signal Transduct Target Ther, Mol Cell, and Cancer Immunol Res and holds an H-index of 9. 🧪 Dr. Xie is a recipient of multiple national honors and leads NSFC-funded research advancing disease-related molecular mechanisms.

Publication Profile

orcid

Education

Assoc. Prof. Dr. Chen Xie is a dedicated researcher with a strong background in biochemical and genetic sciences. He began his academic journey with a Bachelor’s degree in Bioengineering from Huaqiao University 🎓 (2007–2011), followed by a Master’s in Genetics from Sun Yat-Sen University 🔬 (2011–2014). He earned his Ph.D. in Biochemical Engineering in 2018 🧪. Dr. Xie completed a postdoctoral fellowship at Sun Yat-Sen University (2018–2021), and then served as Assistant Professor (2021–2025). Since March 2025, he has been an Associate Professor at the Medical Research Center, Eighth Affiliated Hospital of Sun Yat-Sen University 🏥, advancing biomedical research.

Experience

Assoc. Prof. Dr. Chen Xie mainly focuses on exploring the intricate relationship between inflammation, DNA damage, cellular senescence, noncoding RNAs, and human diseases 🧬. His impactful research has earned him prestigious honors such as the National Natural Science Foundation of China award, the National Scholarship 🏅, the First Prize Scholarship of Huaqiao University, and the Alumni Scholarship 🎓. Dr. Xie has published 8 influential papers in top-tier journals including Signal Transduction and Targeted Therapy, Molecular Cell, and Cancer Immunology Research 📚. With an H-index of 9, he continues to contribute significantly to biomedical science 🧫.

Awards

Assoc. Prof. Dr. Chen Xie has received several prestigious awards in recognition of his academic excellence and research contributions 🎓. He was honored with a National Scholarship for his outstanding performance and dedication to scientific advancement. During his studies at Huaqiao University, he earned the First Prize Scholarship 🥇, highlighting his exceptional academic achievements. Additionally, he received an Alumni Scholarship, reflecting the strong support and recognition from his academic community 🌟. These accolades underscore Dr. Xie’s commitment to excellence in the fields of biochemical engineering, genetics, and biomedical research 🔬.

Research Focus

Assoc. Prof. Dr. Chen Xie is a leading researcher in the fields of molecular biology, epigenetics, and cellular senescence, with a strong emphasis on mechanisms of vascular and pulmonary aging, DNA damage repair, and RNA modifications (e.g., m6A). 🧬 His work uncovers how factors like GATA6, YTHDC1, and FTO regulate aging, fibrosis, cancer, and immune responses, often via intricate signaling pathways and RNA interactions. 🧠🧫 He contributes significantly to understanding vascular calcification, fibrosis, and glioma biology, advancing targeted therapies. His research bridges cellular aging and precision medicine, making a profound impact on age-related and inflammatory diseases.

Publication Top Notes

The transcription factor GATA6 accelerates vascular smooth muscle cell senescence-related arterial calcification by counteracting the role of anti-aging factor SIRT6 and impeding DNA damage repair

YTHDC1 delays cellular senescence and pulmonary fibrosis by activating ATR in an m6A-independent manner

C5a-C5aR1 induces endoplasmic reticulum stress to accelerate vascular calcification <i>via</i> PERK-eIF2α-ATF4-CREB3L1 pathway

UBQLN1 deficiency mediates telomere shortening and IPF through interacting with RPA1

Data from FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma

Supplementary Data from FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma

cGAS guards against chromosome end-to-end fusions during mitosis and facilitates replicative senescence

Therapeutic potential of C1632 by inhibition of SARS-CoV-2 replication and viral-induced inflammation through upregulating let-7

Dr. ANTHOULA LAZARIS| Precision Medicine|Best Researcher Award

Published on by Top Pharmaceutical

Dr. ANTHOULA LAZARIS, Precision Medicine,Best Researcher Award

Dr. ANTHOULA LAZARIS, at MCGILL UNIV. HEALTH CTR,Canada

PROFILE

scopus

📚 Early Academic Pursuits :

Anthoula Lazaris began her academic journey with a B.Sc. in Microbiology and Immunology from McGill University (1983-1986), where she developed a solid foundation in the biological sciences. She continued at McGill, earning a Ph.D. in Biochemistry from the Faculty of Medicine (1988-1992). Her postdoctoral studies took her to Leiden, The Netherlands, where she further honed her expertise in Medical Biochemistry (1992-1994). This robust educational background laid the groundwork for her illustrious career in academia and biotechnology.

🏢Professional Endeavors :

Lazaris has accumulated over 30 years of combined experience in academia and industry, holding management and senior-level positions. Currently, she is a scientist at the Research Institute of the McGill University Health Centre (RI-MUHC), focusing on metastatic and metabolic diseases with an emphasis on translational research. Her career highlights include:

  • Liver Disease Biobank: In 2011, Lazaris established a Liver Disease Biobank in collaboration with Dr. P Metrakos, collecting biospecimens from patients with liver-related diseases.
  • Quebec Extracellular Vesicle Consortium: She spearheaded this consortium with Drs. Rak and Olivier, demonstrating her leadership in collaborative research initiatives.
  • CIHR Training Grant: Lazaris co-wrote and secured a substantial CIHR training grant for the Goodman Cancer Centre, illustrating her proficiency in obtaining competitive funding.

🔬Contributions and Research Focus :

Lazaris’s research contributions span several critical areas:

  • Metastatic Disease: She focuses on colorectal cancer liver metastases (CRCLM), investigating molecular mechanisms to predict therapeutic responses and developing new biomarkers.
  • Translational Research: Her work bridges basic and clinical research, aiming to translate findings into precision therapies for cancer patients. Notably, her research on predictors of therapeutic responses to antiangiogenic agents has been groundbreaking.
  • Liver Diseases: Lazaris’s research also covers hepatocellular carcinoma, cholangiocarcinomas, and NAFLD/NASH, contributing to the broader understanding of these conditions.

🏆Accolades and Recognition :

Throughout her career, Lazaris has received numerous accolades:

  • Scientific American Award: In 2002, she was recognized in the category of Research Leader in Chemical and Materials for her work on transgenic animals producing spider silk.
  • Genome Canada White Paper: She spearheaded the writing of a white paper on “Disease Mechanisms,” which was integrated into Genome Quebec’s strategic plan.
  • Scientific Publications: Her research has been published in prestigious journals like Nature and Science, highlighting her contributions to molecular biology and oncology.

🌍Impact and Influence :

Lazaris’s work has had a profound impact on both the scientific community and public health:

  • Innovations in Biotechnology: She was part of the team that demonstrated the first expression of soluble spider silk, which can be spun into fibers with remarkable mechanical properties.
  • Transgenic Research Network: As the Executive Director of the Quebec Transgenic Research Network, Lazaris unified the capabilities of researchers across Quebec, securing significant funding and fostering collaborative research.
  • Cloned Animals: She was part of the team that generated the world’s first cloned goat and Canada’s first large transgenic animal, showcasing her pioneering contributions to genetic engineering.

🌟Legacy and Future Contributions :

Anthoula Lazaris’s legacy is marked by her pioneering research, leadership in collaborative scientific endeavors, and significant contributions to translational medicine. Her work continues to influence the fields of molecular biology, biotechnology, and cancer research. Looking forward, Lazaris is expected to further her contributions to personalized medicine, leveraging her extensive experience and innovative approach to address pressing challenges in healthcare. Her dedication to translational research and collaborative spirit ensures that her impact will be felt for years to come.

🎓Publication 

Predictive biomarker discovery in cancer using a unique AI model based on set theory

Hepatic stellate cell stearoyl co-A desaturase activates leukotriene B4 receptor 2 – β-catenin cascade to promote liver tumorigenesis

    • Authors :Sinha, S., Aizawa, S., Nakano, Y., … Guccione, E., Tsukamoto, H.
    • Journal   :Nature Communications
    • Year       : 2023

Targeting Liver Metastases to Potentiate Immunotherapy in MS-Stable Colorectal Cancer—A Review of the Literature

  • Authors  :, Zlotnik, O., Krzywon, L., Bloom, J., … Lazaris, A., Metrakos, P.
  • Journal    :Cancers
  • Year         :  2023

Isolation of extracellular vesicles from human plasma samples: The importance of controls

  • Authors  :Tsamchoe, M., Petrillo, S., Lazaris, A., Metrakos, P.
  • Journal   : Biotechnology Journal
  • Year        :   2023

A Retrospective Study on the Role of Metformin in Colorectal Cancer Liver Metastases

  • Authors  :Rada, M., Krzywon, L., Petrillo, S., Lazaris, A., Metrakos, P.
  • Journal   : Biotechnology 
  • Year        :  2023